Navigation Links
Inverness - Chemogen Establish Exclusive License for TB Antibodies

WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Inverness Medical Innovations (Amex: IMA) today announced that it has entered into an agreement with Chemogen, Inc. for the worldwide manufacture and distribution of tests for the rapid detection of Mycobacterium, the primary causative agent of tuberculosis. The tests will utilize Chemogen's proprietary antibodies for the detection of Lipoarabinomannan (LAM) antigen in urine as an aid in the diagnosis of current mycobacterial infection (including Tuberculosis), especially in those patients who are HIV positive.

Commenting on the agreement, Ron Zwanziger, CEO of Inverness, said, "HIV is driving a deadly resurgence of TB on a global scale, claiming nearly 2 million lives annually in recent years. The need for reliable TB diagnosis in HIV co-infected populations has become a top priority, especially in the developing world where these two pandemics are taking a devastating toll on human populations. Inverness is already a leading provider of rapid HIV diagnostic tests to these areas and the availability of a reliable test that can diagnose tuberculosis in HIV-infected patients will be a major step forward in the control of the disease."

In addition to the immediate launch of an already developed and highly sensitive ELISA test to endemic regions, Inverness plans to complete the development of a rapid point of care assay that will reliably and rapidly detect LAM in urine samples, using its proprietary lateral flow technology.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts. For additional information on Inverness Medical Innovations, please visit

About Chemogen

Chemogen is an emerging biotechnology company focused on the development and commercialization of novel and proprietary technology for the rapid diagnosis of infectious diseases.

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding possible margin improvements. Actual results may differ materially due to numerous factors, including without limitation, the ability of Inverness to develop and commercialize new products and obtain regulatory approvals; the ability of Inverness to successfully and efficiently manufacture products; future demand for and costs of the Inverness' products; and the risks and uncertainties described in Inverness' periodic reports filed with the Securities and Exchange Commission under the federal securities laws, including Inverness' Annual Report on Form 10-K for the year ended December 31, 2006, as amended. Inverness undertakes no obligation to update any forward-looking statements.

SOURCE Inverness Medical Innovations
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
4. European Centre for Modern Drug Discovery Established in Hamburg
5. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
6. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
7. KGI and Smith College Establish Leadership Forum for Women in Bioscience
8. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
9. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
10. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, will present at ... week in New York City . The ... December 1, 2015 at 9:30 a.m. EST. ... the website at least 15 minutes prior to the presentation ...
(Date:11/23/2015)... Calif., Nov. 23, 2015   Ceres, Inc . ... today financial results for the fiscal year ended August ... --> --> During ... forage and feed products with a better balance of ... signed distribution agreements with several leading crop input providers ...
(Date:11/23/2015)... PISCATAWAY, New Jersey , November 23, ... Centre (CCDC) announces the launch of the ... and the CSD-System, now complemented by three powerful ... support the discovery of new molecules, CSD-Materials for ... complete set of the CCDC,s applications incorporating CSD-Discovery ...
(Date:11/23/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... ), a biotechnology company focused on the discovery, ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific ... children, doctors and other healthcare providers face challenges in ... families and patients. In addition, as more children continue ... a patient,s adulthood and old age. John ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
Breaking Biology News(10 mins):